Within atherosclerotic plaques, macrophages can take up cholesterol and thereby become lipid-laden cells. For long it has been thought that these foamy macrophages are the main contributors to chronic inflammatory responses in plaques. However, several publications lately highlighted
Consequently, disrupting lipid droplet formation in TAMs in vivo prevented the formation of a pro-tumor macrophage phenotype and impeded tumor growth. As such, the authors propose a potential therapeutic strategy that targets pro-tumor macrophages at an immunometabolic level.
Altogether, these discoveries in cardiovascular and cancer research indicate that lipid accumulation does not directly drive inflammation and rather elicits a suppressive macrophage phenotype. As such, we could consider lipid-laden macrophages as laidback couch potatoes that hang out without stoking inflammation and immunity? Maybe this is not the best description since they are not just passive and can actively suppress inflammation and anti-tumor immunity. Undoubtedly, recent literature demonstrates that lipid-laden macrophage are clearly less inflammatory than the current dogma states. This challenges the research community to
have a more open vision on macrophage subtypes and their roles in disease progression.
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